Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID-19 vaccines safe for people with history of severe allergies, study finds

10/26/2021 | 11:23am EST

People with a history of severe allergic reactions to drugs and vaccines can receive both doses of the two-shot COVID-19 inoculations safely, a study published Tuesday by JAMA Network Open found.

Nearly 12% of healthcare workers who reported having a history of allergies to medications, vaccines or allergens such as dust and pollen had an allergic reaction to either the first or second dose of the COVID-19 vaccine, the data showed.

The most common allergic symptoms were hives and angioedema, or swelling, around the injection site, and none of them required hospital treatment, they said.

Despite these symptoms, 98% of the study participants were fully vaccinated against the virus, meaning they received both doses of the two-shot vaccines from Moderna or Pfizer-BioNTech.

"The results of this study can help guide expectations for patients with high-risk allergy histories," study co-author Dr. Lily Li said in a press release.

"Symptoms such as hives and swelling may occur, particularly with the first vaccine dose, but most reported allergic symptoms did not impede completion of the two-dose mRNA vaccine series," said Li, a member of the allergy faculty at Brigham and Women's Hospital in Boston.

Earlier studies have indicated that allergic reactions to the two-dose COVID-19 vaccines are rare, even among those with a history of allergies.

Severe allergic reactions such as anaphylaxis, or an extreme immune system response to the vaccines, are also extremely rare, research suggests.

For this study, Li and her colleagues assessed allergy risk among 52,998 healthcare workers in the Brigham and Women's health system, all of whom received at least one dose of a COVID-19 vaccine.

More than 60% of the staff members were given the Moderna vaccine, while the rest received the Pfizer-BioNTech shot, the researchers said.

Among all the study participants, 474, or about 1%, reported a history of severe allergic reactions to medications, vaccines or allergens.

While 12% of those with a history of allergic reactions had one after the vaccine, fewer than 5% of those who did not have a history of allergies had one, the researchers said.

Those with a history of allergic reactions had a 2.5-fold higher risk for allergic reactions to the COVID-19 vaccines, the data showed.

The findings should provide reassurance regarding the safety of mRNA COVID-19 vaccination in individuals regardless of allergy history, the researchers said.

"We hope these data will help inform ongoing conversations with patients who are hesitant to receive COVID-19 vaccination due to allergy concerns," co-author Dr. Kimberly G. Blumenthal said in a press release.

"At our institutions, nearly all individuals with and without a history of high-risk allergy were able to complete the two-dose vaccine series," said Blumenthal, co-director of the Clinical Epidemiology Program at Massachusetts General Hospital in Boston.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

All news about MODERNA, INC.
03:25pU.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
03:16pU.S. CDC Says Delivered 580,893,145 Doses Of Covid-19 Vaccine As Of Dec 3
03:15pU.S. CDC Reports Total Novel Coronavirus Cases Of 48,767,329 As Of Yesterday
12:15pVaccine makers could make Omicron-specific booster, says Fauci
12:02pPUMP / DUMP #13 : This week's gainers and losers
01:21aUK jabs deal to 'future-proof' immunisation
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
12/02U.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
12/02U.S. CDC Says Delivered 578,263,565 Doses Of COVID-19 Vaccine As Of Dec 2
12/02US Stocks Rebound Following Recent Sell-Offs as Omicron Variant Concerns Subside
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Capitalization 124 B 124 B -
EV / Sales 2021 6,42x
EV / Sales 2022 4,93x
Nbr of Employees 1 300
Free-Float 90,5%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Last Close Price 306,72 $
Average target price 272,53 $
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745